Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Rudin

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Plos One|August 28, 2025
Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritisTilia Selldén, Kerstin Andersson, Inger Gjertsson, et al.
Lupus Science & Medicine|May 18, 2026
Comparison of BAFF and type I IFN activity in blood and placenta in SLE and healthy pregnanciesAgnes Torell, Kerstin Andersson, Iva Gunnarsson, et al.
The Lancet. Rheumatology|January 24, 2024
Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trialKristina Lend, Ronald F van Vollenhoven, Jon Lampa, et al.
Annals of the Rheumatic Diseases|July 30, 2024
Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trialKristina Lend, Jon Lampa, Leonid Padyukov, et al.
Journal of Translational Autoimmunity|September 2, 2025
Acylcarnitine enrichment as a characteristic of rheumatoid arthritis fibroblast-like synoviocyte metabolic fingerprintGeorgios K Vasileiadis, Yuan Zhang, Marion Laudette, et al.
Annals of the Rheumatic Diseases|March 9, 2026
Hand-dominant joint involvement pattern associates with favourable, and polyarthritis with unfavourable, treatment response to both csDMARDs and bDMARDs in early rheumatoid arthritis: a combined analysis of NORD-STAR and BeSt trialsYasuo Nagafuchi, Tjardo D Maarseveen, Kristina Lend, et al.
ACR Open Rheumatology|October 16, 2024
Circulating Baseline CXCR3<sup>+</sup>Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid ArthritisJulia M Scheffler, Christina Drevinge, Catharina Lindholm, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 12, 2021
Human Cord Blood B Cells Differ from the Adult Counterpart by Conserved Ig Repertoires and Accelerated Response DynamicsBettina Budeus, Artur Kibler, Martina Brauser, et al.
RMD Open|April 5, 2024
Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR studyVioletta Dubovyk, Georgios K Vasileiadis, Tahzeeb Fatima, et al.
BMJ (Clinical Research Ed.)|December 3, 2020
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trialMerete Lund Hetland, Espen A Haavardsholm, Anna Rudin, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Plos One|August 28, 2025
Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritisTilia Selldén, Kerstin Andersson, Inger Gjertsson, et al.
Lupus Science & Medicine|May 18, 2026
Comparison of BAFF and type I IFN activity in blood and placenta in SLE and healthy pregnanciesAgnes Torell, Kerstin Andersson, Iva Gunnarsson, et al.
The Lancet. Rheumatology|January 24, 2024
Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trialKristina Lend, Ronald F van Vollenhoven, Jon Lampa, et al.
Annals of the Rheumatic Diseases|July 30, 2024
Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trialKristina Lend, Jon Lampa, Leonid Padyukov, et al.
Journal of Translational Autoimmunity|September 2, 2025
Acylcarnitine enrichment as a characteristic of rheumatoid arthritis fibroblast-like synoviocyte metabolic fingerprintGeorgios K Vasileiadis, Yuan Zhang, Marion Laudette, et al.
Annals of the Rheumatic Diseases|March 9, 2026
Hand-dominant joint involvement pattern associates with favourable, and polyarthritis with unfavourable, treatment response to both csDMARDs and bDMARDs in early rheumatoid arthritis: a combined analysis of NORD-STAR and BeSt trialsYasuo Nagafuchi, Tjardo D Maarseveen, Kristina Lend, et al.
ACR Open Rheumatology|October 16, 2024
Circulating Baseline CXCR3<sup>+</sup>Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid ArthritisJulia M Scheffler, Christina Drevinge, Catharina Lindholm, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 12, 2021
Human Cord Blood B Cells Differ from the Adult Counterpart by Conserved Ig Repertoires and Accelerated Response DynamicsBettina Budeus, Artur Kibler, Martina Brauser, et al.
RMD Open|April 5, 2024
Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR studyVioletta Dubovyk, Georgios K Vasileiadis, Tahzeeb Fatima, et al.
BMJ (Clinical Research Ed.)|December 3, 2020
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trialMerete Lund Hetland, Espen A Haavardsholm, Anna Rudin, et al.
Pageof 10